A detailed history of Creative Planning transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Creative Planning holds 39,871 shares of AVXL stock, worth $297,038. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,871
Previous 25,861 54.17%
Holding current value
$297,038
Previous $109,000 107.34%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$4.11 - $7.04 $57,581 - $98,630
14,010 Added 54.17%
39,871 $226,000
Q2 2024

Aug 15, 2024

BUY
$3.39 - $5.02 $5,864 - $8,684
1,730 Added 7.17%
25,861 $109,000
Q1 2024

May 10, 2024

BUY
$4.55 - $6.75 $25,370 - $37,638
5,576 Added 30.05%
24,131 $122,000
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $34,161 - $67,441
6,778 Added 57.55%
18,555 $172,000
Q3 2023

Nov 16, 2023

SELL
$6.55 - $9.37 $7,591 - $10,859
-1,159 Reduced 8.96%
11,777 $77,000
Q2 2023

Jul 21, 2023

SELL
$7.66 - $9.5 $1,363 - $1,691
-178 Reduced 1.36%
12,936 $105,000
Q1 2023

May 15, 2023

SELL
$8.32 - $11.75 $5,724 - $8,084
-688 Reduced 4.98%
13,114 $112,000
Q4 2022

Feb 10, 2023

SELL
$7.65 - $14.43 $46,764 - $88,210
-6,113 Reduced 30.7%
13,802 $127,000
Q3 2022

Nov 03, 2022

SELL
$8.9 - $12.86 $142,400 - $205,760
-16,000 Reduced 44.55%
19,915 $206,000
Q2 2022

Aug 15, 2022

BUY
$7.31 - $12.84 $19,737 - $34,668
2,700 Added 8.13%
35,915 $360,000
Q1 2022

May 16, 2022

BUY
$9.74 - $17.69 $123,698 - $224,663
12,700 Added 61.91%
33,215 $409,000
Q4 2021

Feb 11, 2022

BUY
$16.88 - $23.31 $346,293 - $478,204
20,515 New
20,515 $356,000
Q2 2021

Aug 04, 2021

SELL
$10.16 - $28.86 $180,340 - $512,265
-17,750 Closed
0 $0
Q1 2021

Apr 30, 2021

BUY
$5.17 - $16.13 $91,767 - $286,307
17,750 New
17,750 $265,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $581M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.